A Man and His Dog Go Viral for Taking Antidepressants Together in This Wholesome Video Series

Both Cornwell and his dog, Cammie, a boxer-beagle mix, take a daily medication called a selective serotonin reuptake ...
Medscape

PANDA Revisited: Sertraline’s Early Benefit Missed

A reanalysis of the PANDA trial suggests sertraline eases low mood and anxiety within 2 weeks, effects that the original ...

US FDA expands use of J&J's Caplyta as add-on depression drug

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on ...
MedPage Today on MSN

FDA Broadens Caplyta Approval to Include Major Depression

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...
Nottinghamshire Live on MSN

DVLA warning as drivers could lose licence over three common medications

The DVLA has issued a warning to drivers, road users and motorists that they could have their driving licence revoked if they ...
The Canadian Press on MSN

Menopause care is more widely available, but financially out of reach for many

Karine Beauchamp couldn't think straight, felt so exhausted she could barely get out of bed and had unpredictable mood swings ...
News-Medical.Net on MSN

Can creatine help with depression? New review says results are inconclusive

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...
PharmExec

FDA Approves Johnson and Johnson’s Caplyta

Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
Fierce Pharma

J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
pharmaphorum

J&J adds first new indication for Caplyta since takeover

The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
MPR

FDA Greenlights Caplyta for Adjunctive Use in MDD

The Food and Drug Administration (FDA) has approved Caplyta ® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
Stocktwits on MSN

Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder

The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...